Literature DB >> 1563216

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

C C Peck1, W H Barr, L Z Benet, J Collins, R E Desjardins, D E Furst, J G Harter, G Levy, T Ludden, J H Rodman.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1563216     DOI： 10.1038/clpt.1992.47

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  37 in total

Review 1.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors:  L J Lesko; M Rowland; C C Peck; T F Blaschke
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.

Authors:  C Chen
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 3.  The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.

Authors:  Patrick J Marroum; Jogarao Gobburu
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 5.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

Review 6.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

Review 7.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.

Authors:  Mark Penney; Balaji Agoram
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 9.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 10.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.